Literature DB >> 15342818

Imatinib mesylate for cerebral Langerhans'-cell histiocytosis.

Liliana Montella, Luigi Insabato, Giovannella Palmieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15342818     DOI： 10.1056/NEJM200409023511022

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

1.  Neuro-oncology in a nutshell.

Authors:  Joachim M Baehring
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

2.  A tale of two histiocytic disorders.

Authors:  Filip Janku; Javier Munoz; Vivek Subbiah; Razelle Kurzrock
Journal:  Oncologist       Date:  2013-01-08

3.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

Review 4.  Transplantation in rare lymphoproliferative and histiocytic disorders.

Authors:  Alexis Cruz-Chacon; John Mathews; Ernesto Ayala
Journal:  Cancer Control       Date:  2014-10       Impact factor: 3.302

5.  Spontaneous remission of 2-chlorodeoxyadenosine (2-CdA)-related secondary myelodysplastic syndrome in a patient with refractory Langerhans cell histiocytosis.

Authors:  Daisuke Suzuki; Ryoji Kobayashi; Hirozumi Sano; Kenji Kishimoto; Kazue Yasuda; Masanori Nakanishi; Tetsuro Nagashima; Kunihiko Kobayashi
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

6.  Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis.

Authors:  Liliana Montella; Carmela Merola; Geraldina Merola; Luigi Petillo; Giovannella Palmieri
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

7.  Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.

Authors:  Dmitry Evseev; Irina Kalinina; Elena Raykina; Daria Osipova; Zalina Abashidze; Anna Ignatova; Anna Mitrofanova; Alexey Maschan; Galina Novichkova; Michael Maschan
Journal:  Int J Hematol       Date:  2021-08-12       Impact factor: 2.490

Review 8.  Langerhans cell histiocytosis.

Authors:  Joan Manel Gasent Blesa; Vicente Alberola Candel; Carlos Solano Vercet; Juan Laforga Canales; Christof Semler; Maria Rosa Pérez Antolí; Carlos Rodríguez-Galindo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.340

Review 9.  Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net.

Authors:  Michael Girschikofsky; Maurizio Arico; Diego Castillo; Anthony Chu; Claus Doberauer; Joachim Fichter; Julien Haroche; Gregory A Kaltsas; Polyzois Makras; Angelo V Marzano; Mathilde de Menthon; Oliver Micke; Emanuela Passoni; Heinrich M Seegenschmiedt; Abdellatif Tazi; Kenneth L McClain
Journal:  Orphanet J Rare Dis       Date:  2013-05-14       Impact factor: 4.123

10.  Potential clinical implications of BRAF mutations in histiocytic proliferations.

Authors:  Anna-Maria Bubolz; Stephanie E Weissinger; Albrecht Stenzinger; Annette Arndt; Konrad Steinestel; Silke Brüderlein; Holger Cario; Anneli Lubatschofski; Claudia Welke; Ioannis Anagnostopoulos; Thomas F E Barth; Ambros J Beer; Peter Möller; Martin Gottstein; Andreas Viardot; Jochen K Lennerz
Journal:  Oncotarget       Date:  2014-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.